Brokers Set Expectations for HealthEquity, Inc.’s FY2026 Earnings (NASDAQ:HQY)

HealthEquity, Inc. (NASDAQ:HQY) – Zacks Research lowered their FY2026 earnings per share (EPS) estimates for HealthEquity in a research report issued on Monday, September 30th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $2.80 per share for the year, down from their previous forecast of $2.81. The consensus estimate for HealthEquity’s current full-year earnings is $2.25 per share. Zacks Research also issued estimates for HealthEquity’s FY2027 earnings at $3.54 EPS.

A number of other research firms have also weighed in on HQY. Raymond James boosted their target price on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Friday, June 7th. Wells Fargo & Company boosted their target price on HealthEquity from $107.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, June 20th. Bank of America lowered their target price on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft upped their price target on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $92.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $103.83.

HealthEquity Trading Up 6.3 %

NASDAQ HQY opened at $83.09 on Thursday. HealthEquity has a 1-year low of $61.81 and a 1-year high of $88.26. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock has a 50-day moving average of $76.43 and a 200-day moving average of $79.20. The firm has a market cap of $7.23 billion, a PE ratio of 89.13, a price-to-earnings-growth ratio of 1.25 and a beta of 0.52.

HealthEquity (NASDAQ:HQY) last released its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The company had revenue of $299.93 million during the quarter, compared to analyst estimates of $284.48 million.

Insider Transactions at HealthEquity

In other news, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the transaction, the insider now owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the transaction, the insider now owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Frank Corvino sold 1,247 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the transaction, the director now directly owns 4,823 shares of the company’s stock, valued at $387,093.98. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,952 shares of company stock valued at $3,526,147. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Forest Hill Capital LLC bought a new position in HealthEquity during the 4th quarter valued at approximately $2,021,000. Vanguard Group Inc. increased its holdings in shares of HealthEquity by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock worth $715,783,000 after purchasing an additional 149,133 shares in the last quarter. Diversify Advisory Services LLC bought a new stake in shares of HealthEquity in the 1st quarter worth $7,828,000. Vaughan Nelson Investment Management L.P. bought a new stake in shares of HealthEquity in the 1st quarter worth $49,443,000. Finally, Lisanti Capital Growth LLC bought a new stake in shares of HealthEquity in the 1st quarter worth $4,701,000. Institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.